KR930017582A - Superoxide Dismutase Stabilizing Composition - Google Patents

Superoxide Dismutase Stabilizing Composition Download PDF

Info

Publication number
KR930017582A
KR930017582A KR1019920003013A KR920003013A KR930017582A KR 930017582 A KR930017582 A KR 930017582A KR 1019920003013 A KR1019920003013 A KR 1019920003013A KR 920003013 A KR920003013 A KR 920003013A KR 930017582 A KR930017582 A KR 930017582A
Authority
KR
South Korea
Prior art keywords
acid
composition
polyoxyethylene
molecular weight
superoxide dismutase
Prior art date
Application number
KR1019920003013A
Other languages
Korean (ko)
Inventor
오순균
이삼수
조상현
어성국
권영성
송찬호
한경희
정연숙
Original Assignee
최근선
주식회사 럭 키
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 최근선, 주식회사 럭 키 filed Critical 최근선
Priority to KR1019920003013A priority Critical patent/KR930017582A/en
Publication of KR930017582A publication Critical patent/KR930017582A/en

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

본 발명은 수퍼옥사이드 디스무타제와 약학적으로 허용되는 아미노산, 당류, 단백질류, 고분자화합물류 및 계면활성제류중에서 선택된 1종 이상의 물질을 조합시킴으로써 수퍼옥사이드 디스무타제를 안정화시킨 조성물을 제공하는 것이다.The present invention provides a composition in which a superoxide dismutase is stabilized by combining a superoxide dismutase with at least one substance selected from pharmaceutically acceptable amino acids, sugars, proteins, polymer compounds, and surfactants. .

Description

수퍼옥사이드 디스무타제 안정화 조성물Superoxide Dismutase Stabilizing Composition

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 본 발명에 따른 글리신에 의한 수퍼옥사이드 디스무타제의 안정화 효과를 도시한 그래프이고, 제2도는 본 발명에 따른 만니톨에 의한 수퍼옥사이드 디스무타제의 안정화 효과를 도시한 그래프이며, 제3도는 본 발명에 따른 덱스트란에 의한 수퍼옥사이드 디스무타제의 안정화 효과를 도시한 그래프이다.1 is a graph showing the stabilizing effect of the superoxide dismutase by glycine according to the present invention, Figure 2 is a graph showing the stabilizing effect of the superoxide dismutase by mannitol according to the present invention, Figure is a graph showing the stabilizing effect of the superoxide dismutase by dextran according to the present invention.

Claims (14)

수퍼옥사이드 디스무타제 와 약리학적으로 허용되는 아미노산, 당류, 단백질류, 고분자화합물류 및 계면활성게류 중에서 선택된 1종 이상의 물질을 포함하는 수퍼옥사이드 디스무타제 안정화 조성물.A superoxide dismutase stabilizing composition comprising a superoxide dismutase and at least one substance selected from pharmacologically acceptable amino acids, sugars, proteins, polymer compounds and surfactants. 제1항에 있어서, 상기 수퍼옥사이드 디스무타제가 인가 Cu,Zu-수퍼옥사이드 디스무타제인 조성물.The composition of claim 1 wherein said superoxide dismutase is applied Cu, Zu- superoxide dismutase. 제1항에 있어서, 상기 아미노산이 글리신, 알라닌, 로이신, 트레오닌, 트립토판, 리신, 히드록시리신, 히스티딘, 알기닌, 시스테인 및 메티오닌 중에서 선택된 1종이상의 물질인 조성물.The composition of claim 1, wherein the amino acid is at least one substance selected from glycine, alanine, leucine, threonine, tryptophan, lysine, hydroxylysine, histidine, arginine, cysteine and methionine. 제1항 또는 제3항에 있어서, 상기 아미노산을 5내지 50mg/ml의 농도로 포함하는 조성물.4. A composition according to claim 1 or 3 comprising the amino acid at a concentration of 5 to 50 mg / ml. 제1항에 있어서, 상기 당류가 글리세린, 에리트리톨, 아라비톨, 크실리톨, 솔비톨, 만니톨, 글루쿠론산, 이두론론산, 뉴라민산, 갈락투론산, 글루콘산, 만누론산, 케토글루콜산, 케토갈락톤산, 케토구론산, 히아루론산 황산 콘드로이틴 및 그의 염, 헤파린, 인슐린, 키틴 및 그의 유도체, 댁스티린, 5,000 내지 150,000의 평균 분자량을 갖는 데스트란, 알긴산 및 그의 염, 및 10,000 내지 200,000의 평균 분자량을 갖는 히드록시에틸 스타치 중에서 선택된 1종 이상의 물질인 조성물.The saccharide according to claim 1, wherein the saccharide is glycerin, erythritol, arabitol, xylitol, sorbitol, mannitol, glucuronic acid, iduronic acid, neuramic acid, galacturonic acid, gluconic acid, mannuronic acid, ketoglucolic acid , Ketogalactonic acid, ketoguronic acid, hyaluronic acid sulfate chondroitin and salts thereof, heparin, insulin, chitin and derivatives thereof, daxtyrine, destran, alginic acid and salts thereof having an average molecular weight of 5,000 to 150,000, and 10,000 to 200,000 At least one substance selected from hydroxyethyl starches having an average molecular weight. 제1항 또는 5항에 있어서, 상기 당류를 3내지 50mg/ml의 농도로 포함하는 조성물.The composition according to claim 1 or 5, wherein the sugar is contained at a concentration of 3 to 50 mg / ml. 제1항에 있어서, 상기 단백질류가 인간 혈청 알부민, 간 혈청 글로불린, 젤라틴, 평균 분자량 7,000 내지 100,000인 산처리 젤라틴, 평균 분자량이 7,000 내지 100,000인 알칼리 처리 젤라틴 및 콜라겐 중에서 선택된 1종 이상의 물질인 조성물.The composition according to claim 1, wherein the protein is at least one substance selected from human serum albumin, liver serum globulin, gelatin, acid treated gelatin having an average molecular weight of 7,000 to 100,000, alkali treated gelatin and collagen having an average molecular weight of 7,000 to 100,000. . 제1항 또는 7항에 있어서, 상기 단백질류를 2내지 50mg/ml의 농도로 포함하는 조성물.8. The composition of claim 1 or 7, comprising the protein at a concentration of 2 to 50 mg / ml. 제1항에 있어서, 상기 고분자화합물류가 히드록시프로필 셀루로우스, 히드록시 메틸 셀루로오스, 분자량 300 내지 6,000의 폴리에틸렌글리콜, 분자량 20,000 내지 100,000의 폴리비닐알코올, 및 분자량 20,000 내지 100,000의 폴리비닐피로리돈 중에서 선택된 1종 이상의 물질인 조성물.The method of claim 1, wherein the polymer compound is hydroxypropyl cellulose, hydroxy methyl cellulose, polyethylene glycol having a molecular weight of 300 to 6,000, polyvinyl alcohol having a molecular weight of 20,000 to 100,000, and polyvinyl having a molecular weight of 20,000 to 100,000 At least one substance selected from pyrrolidones. 제1항 또는 9항에 있어서, 상기 고분자 화합물류를 2내지 100mg/ml의 농도로 포함하는 조성물.The composition according to claim 1 or 9, wherein the polymer compound is contained at a concentration of 2 to 100 mg / ml. 제1항에 있어서, 상기 계면 활성제류가 솔비탄 지방족산 에스테르, 글리세린 지방족산 에스테르, 폴리글리세린 지방족산 에스테르, 폴리 옥시에틸렌솔비탄 지방족산 에스테르, 폴리옥시에틸렌솔비를 지방족산 에스테르, 폴리에틸렌글리세린 지방족산 에스테르, 폴리에틸렌 글리콜 지방족산 에스테르, 폴리옥시에틸렌 알칼 에테르, 폴리옥시에틸렌 폴리옥시프로필렌 알킬 체테르, 폴리 옥시에틸렌 알켈 페닐 에테르, 폴리옥시에틸화 캐스터오일, 경화된 폴리옥시에틸화 캐스터오일, 폴리옥시에틸화 밀납유도체, 폴리옥시에틸렌 라놀린 유도체 및 폴리옥시에틸렌 지방족산 아미드, 탄소수 10내지 18의 알킬기를 갖는 알킬황산염, 폴리옥시에틸렌 알칼 에테르 황산염, 알킬술포숙시네이트 에스테르 염, 레시틴, 글리세로 포스포리피드 및 스핀고포스포리피드 중에서 선택된 1종 이상의 물질인 조성물.The method of claim 1, wherein the surfactants are sorbitan fatty acid esters, glycerin aliphatic acid esters, polyglycerol aliphatic acid esters, polyoxyethylene sorbitan aliphatic acid esters, polyoxyethylene sorbbi aliphatic acid esters, polyethylene glycerin aliphatic acid Esters, polyethylene glycol aliphatic esters, polyoxyethylene alkaline ethers, polyoxyethylene polyoxypropylene alkyl cheters, polyoxyethylene alkyl phenyl ethers, polyoxyethylated castor oils, cured polyoxyethylated castor oils, polyoxyethyl Beeswax derivatives, polyoxyethylene lanolin derivatives and polyoxyethylene aliphatic acid amides, alkyl sulfates having alkyl groups of 10 to 18 carbon atoms, polyoxyethylene alkaline ether sulfates, alkylsulfosuccinate ester salts, lecithin, glycerophospholipids And spinophosphori The composition of one or more materials that are selected from DE. 제1항에 있어서, 상기 계면활성제류를 0.0001 내지 20%의 농도로 포함하는 조성물.The composition of claim 1 comprising the surfactants at a concentration of 0.0001 to 20%. 제1항에 있어서, 아황상 환원제 및 항산화제중에서 선택된 1종 이상의 물질을 추가로 함유하는 조성물.The composition of claim 1, further comprising at least one substance selected from sulfite reducing agents and antioxidants. 제1항에 있어서, 카탈라아제를 추가로 함유하는 조성물.The composition of claim 1 further comprising catalase. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019920003013A 1992-02-26 1992-02-26 Superoxide Dismutase Stabilizing Composition KR930017582A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019920003013A KR930017582A (en) 1992-02-26 1992-02-26 Superoxide Dismutase Stabilizing Composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019920003013A KR930017582A (en) 1992-02-26 1992-02-26 Superoxide Dismutase Stabilizing Composition

Publications (1)

Publication Number Publication Date
KR930017582A true KR930017582A (en) 1993-09-20

Family

ID=67256941

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920003013A KR930017582A (en) 1992-02-26 1992-02-26 Superoxide Dismutase Stabilizing Composition

Country Status (1)

Country Link
KR (1) KR930017582A (en)

Similar Documents

Publication Publication Date Title
US5925739A (en) Pharmaceutical formulation for subcutaneous intramuscular or intradermal administration of factor VIII
BE1000253A3 (en) Stable pharmaceutical preparation containing an incentive factor granulocyte colony and method for producing.
KR970706017A (en) Stable aqueous alpha-interferon solution formulations
ES2526707T3 (en) Purification and stabilization of peptides and proteins in pharmaceutical agents
DE69516960D1 (en) SULFATED HYALURONIC ACID WITH 0.5 TO LESS THAN 2 SULFATE GROUPS PER UNIT
KR920019371A (en) Stabilized Factor Ⅷ Formulations
JP3950993B2 (en) Pharmaceutical compositions based on taxane derivatives
KR920700679A (en) Lipid excipients for nasal delivery and their use
KR870002835A (en) Pharmaceutical preparation method of ionizable hydrophobic drug
FI874706A0 (en) Process for the preparation of stable pharmaceutical compositions of non-glycosylated recombinant interferon
DE59908745D1 (en) PHARMACEUTICAL CICLOSPORIN FORMULATION WITH IMPROVED BIOPHARMACEUTICAL PROPERTIES, INCREASED PHYSICAL QUALITY & STABILITY AND METHOD FOR THE PRODUCTION THEREOF
UY25055A1 (en) PHARMACEUTICAL FORMULATIONS CONTAINING VORICONAZOLE
KR870010867A (en) Composition for the synthesis of prostaglandins and hydroxy-fatty acids
JP2010100664A (en) Hgf for treating acute renal failure
KR930017582A (en) Superoxide Dismutase Stabilizing Composition
BRPI0416980A (en) stabilized interferon liquid formulations
HK1049789A1 (en) Solubilized pharmaceutical composition for parenteral administration
KR860006982A (en) Method for preparing stable gamma interferon formulation
JPS6360940A (en) Preventive or remedy for cataract
JP4493594B2 (en) Nasal powder formulation
DE69732109D1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AN ALKYLARYL POLYETHER ALCOHOL POLYMER
PT590531E (en) PREPARATION OF ANTITROMBIN III
HU218103B (en) Pharmaceutical composition containing non-glycosylated recombinant human interleukin-2 and process for producing it
Hayashi et al. Effect of beraprost, a stable prostacyclin analogue, on red blood cell deformability impairment in the presence of hypercholesterolemia in rabbits
Bird et al. Some possible mechanisms of action of an endogenous anti-inflammatory protein [proceedings]

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application